Amnion epithelial cells——a novel therapy for ischemic stroke?  

作　　者：Megan A.Evans Brad R.S.Broughton Grant R.Drummond Henry Ma Thanh G.Phan Euan M.Wallace Rebecca Lim Christopher G.Sobey 

机构地区：[1]Department of Physiology, Anatomy & Microbiology, La Trobe University [2]Cardiovascular Disease Program, Department of Pharmacology, Biomedicine Discovery Institute, Monash University [3]Department of Medicine, Monash University [4]The Ritchie Centre, Hudson Institute of Medical Research [5]Department of Obstetrics and Gynaecology, Monash University

出　　处：《Neural Regeneration Research》2018年第8期1346-1349,共4页中国神经再生研究（英文版）

摘　　要：Stroke is a leading cause of death and disability and new therapies are desperately needed. Given the complex nature of ischemic brain injury, it has been postulated that cell-based therapies may be useful. However, cell resources, invasive extraction procedures, immunological rejection, tumorigenesis and ethical challenges make it unlikely that many stem cell types could serve as a practical source for therapy. By contrast, these issues do not pertain to human amnion epithelial cells（h AECs）, which are placenta-derived stem cells. We recently assessed the effects of systemically delivered hAECs on stroke outcome using four animal models of stroke. We demonstrated that when injected intravenously after ischemia onset, hAECs migrate preferentially to the spleen and injured brain to limit apoptosis and inflammation, and attenuate early brain infiltration of immune cells, progression of infarction and systemic immunosuppression and to ultimately ameliorate functional deficits. When administration of hAECs is delayed by 1-3 days poststroke, long-term functional recovery can still be enhanced in young and aged mice of either sex. Moreover, our proof-of-principle findings suggest that h AECs are effective at limiting post-stroke infarct development in non-human primates. Overall, the results suggest that hAECs could be a viable clinical stroke therapy.Stroke is a leading cause of death and disability and new therapies are desperately needed. Given the complex nature of ischemic brain injury, it has been postulated that cell-based therapies may be useful. However, cell resources, invasive extraction procedures, immunological rejection, tumorigenesis and ethical challenges make it unlikely that many stem cell types could serve as a practical source for therapy. By contrast, these issues do not pertain to human amnion epithelial cells（h AECs）, which are placenta-derived stem cells. We recently assessed the effects of systemically delivered hAECs on stroke outcome using four animal models of stroke. We demonstrated that when injected intravenously after ischemia onset, hAECs migrate preferentially to the spleen and injured brain to limit apoptosis and inflammation, and attenuate early brain infiltration of immune cells, progression of infarction and systemic immunosuppression and to ultimately ameliorate functional deficits. When administration of hAECs is delayed by 1-3 days poststroke, long-term functional recovery can still be enhanced in young and aged mice of either sex. Moreover, our proof-of-principle findings suggest that h AECs are effective at limiting post-stroke infarct development in non-human primates. Overall, the results suggest that hAECs could be a viable clinical stroke therapy.

关 键 词：ischemic stroke cerebral infarction stem cells human amnion epithelial cells INFLAMMATION IMMUNOSUPPRESSION brain repair MOUSE non-human primate 

分 类 号：R743.3[医药卫生—神经病学与精神病学]